Cognitive · Investigational
Neurotensin
No lawful US pathway
01 · Overview
Neurotensin is a 13-amino acid neuropeptide found in the central nervous system and gastrointestinal tract, where it modulates dopamine neurotransmission, nociception, and intestinal function. It acts mainly through neurotensin receptor 1 (NTSR1), a G protein-coupled receptor that is also overexpressed in several cancers (PMID 42155169).
Because centrally administered neurotensin produces effects resembling antipsychotic drugs, it has been proposed to act as an endogenous antipsychotic (PMID 11743941). Neurotensin has been studied for potential roles in schizophrenia, pain modulation, and cognitive function.
02 · Research summary & key findings
In rats, the brain-penetrant neurotensin analog NT69L blocked phencyclidine-induced hyperactivity and prefrontal neurotransmitter surges, an antipsychotic-like effect in an animal model (PMID 19948149). In people with schizophrenia, lower cerebrospinal fluid neurotensin was associated with more severe symptoms, and rises in CSF neurotensin during antipsychotic treatment correlated with improvement (PMID 9210757). No neurotensin-based treatment for psychiatric or cognitive disorders has reached clinical trials, but neurotensin receptor-targeted radiopharmaceuticals have entered clinical trials for cancer (PMID 42155169), including a first-in-human study of a radiolabeled neurotensin PET tracer for prostate cancer imaging (PMID 42304982).
03 · Regulatory status
Neurotensin is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
No lawful pathway today
Neurotensin is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for cognitive support?
Neurotensin is an investigational compound, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on cognitive support, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Intravenous
- Intracerebroventricular
References
- [1]The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs Biol Psychiatry, 2001. PMID 11743941
- [2]The novel neurotensin analog NT69L blocks phencyclidine (PCP)-induced increases in locomotor activity and PCP-induced increases in monoamine and amino acids levels in the medial prefrontal cortex Brain Res, 2010. PMID 19948149
- [3]Advances in research on radiopharmaceuticals targeting NTSR1 Eur J Med Chem, 2026. PMID 42155169
- [4]First-in-human evaluation of [(18)F]-AlF-NOTA-neurotensin for NTSR1-targeted imaging of prostate cancer: a head-to-head comparison with [(68)Ga]Ga-PSMA-617 Ann Med, 2026. PMID 42304982
- [5]CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder Am J Psychiatry, 1997. PMID 9210757
Primary literature
- PubMed: "Neurotensin"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Neurotensin"
Registered interventional and observational studies, including status and phase.
- PubChem: "Neurotensin"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Cognitive
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.